. Author manuscript; available in PMC: 2015 Dec 15.

Published in final edited form as: Arch Biochem Biophys. 2014 Oct 19;0:244–253. doi: 10.1016/j.abb.2014.10.006

Table 2.

Preliminary analysis of kinetic mechanism describing R- and S-7-hydroxywarfarin glucuronidation^a

Substrate	Metabolites^b	Model	Model Preference	Parameters for Preferred Model
Substrate	Metabolites^b	Model	Model Preference	V_max1^c	K_m (μM)	K_i (μM)
R-7-HOWAR	7-HOWAR-4-GLUC	Substrate Inhibition	70.7 %	35.4 (30.4–40.4)	60.8 (36.9–84.8)	2640 (1360–3920)
R-7-HOWAR	7-HOWAR-7-GLUC	Michaelis-Menten	75.2 %	1090 (1040–1140)	122 (100–145)	-
S-7-OHWAR	7-HOWAR-4-GLUC	Substrate Inhibition	>99.99 %	19.7 (17.19–22.2)	111 (77.7–145)	2840 (1650–4030)
S-7-OHWAR	7-HOWAR-7-GLUC	Substrate Inhibition	99.7 %	1470 (790–2150)	929 (362–1500)	1310 (259–2370)

The nonsymmetrical 95 % confidence intervals for parameters are shown in parentheses.

Glucuronidation resulted in conjugation of the hydroxyl group at either the C4 or C7 position resulting in the formation of 7-HOWAR-4-GLUC or 7-HOWAR-7-GLUC, respectively, as described in the Discussion.

Units are nmol/min/mg protein